

Endothelial cell-activating antibodies in COVID-19

Hui Shi^{1,2}, Yu Zuo¹, Alex A. Gandhi¹, Gautam Sule¹, Srilakshmi Yalavarthi¹, Kelsey Gockman¹, Jacqueline A. Madison¹, Jintao Wang⁵, Melanie Zuo³, Yue Shi⁴, Jason S. Knight^{1‡}, and Yogendra Kanthi^{5,6‡}

‡ Jason S. Knight and Yogendra Kanthi are co-corresponding authors

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

² Division of Rheumatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

³ Division of Geriatric and Palliative Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

⁴ School of Kinesiology, Shanghai University of Sport, Shanghai, China

⁵ Division of Intramural Research National Heart, Lung and Blood Institute Bethesda, Maryland, USA

⁶ Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Correspondence: Jason S. Knight, MD, PhD Yogendra Kanthi, MD
jsknight@umich.edu yogen.kanthi@nih.gov

Competing interests: The authors have no relevant financial conflicts to report.

ABSTRACT

Patients with coronavirus disease 19 (**COVID-19**) are at high risk for fibrin-based occlusion of vascular beds of all sizes. Although endothelial cell activation has regularly been described as part of the COVID-19 thrombo-inflammatory storm, the upstream mediators of this activation have yet to be fully elucidated. Here, we began by pursuing the hypothesis that circulating factors such as neutrophil extracellular trap (NET) remnants, D-dimer, or C-reactive protein might predict the COVID-19 serum samples (n=118) that most robustly activated cultured endothelial cells. Indeed, we found modest correlations between serum NET remnants (cell-free DNA, myeloperoxidase-DNA complexes, citrullinated histone H3) and upregulation of surface E-selectin, VCAM-1, and ICAM-1 on endothelial cells. However, a more robust predictor of the ability of COVID-19 serum to activate endothelial cells was the presence of circulating antiphospholipid antibodies, specifically anticardiolipin IgG and IgM and anti-phosphatidylserine/prothrombin (anti-PS/PT) IgG and IgM. Depletion of total IgG from anticardiolipin-high and anti-PS/PT-high samples markedly restrained upregulation of E-selectin, VCAM-1, and ICAM-1. At the same time, supplementation of control serum with patient IgG was sufficient to trigger endothelial cell activation. These data are the first to reveal that patient antibodies are a driver of endothelial cell activation and add important context regarding thrombo-inflammatory effects of COVID-19 autoantibodies in severe COVID-19.

INTRODUCTION

Derangements in coagulation correlate with COVID-19 severity (1, 2). Indeed, there are now myriad reports demonstrating the high risk of both venous thromboembolism (3, 4) and arterial thrombosis including strokes and myocardial infarctions (4, 5) in patients with COVID-19. Furthermore, histopathology of autopsy brain and lung specimens from patients with severe disease demonstrate dysfunctional endothelium and fibrin-based occlusion of small vessels (6-9). There are several (possibly synergistic) mechanisms by which SARS-CoV-2 infection may result in macrovascular and microvascular thrombosis (10) including a cytokine storm that activates leukocytes, endothelium, and platelets; direct activation of various cells by viral infection; and high levels of intravascular neutrophil extracellular traps (**NETs**) (11, 12). The latter are inflammatory cell remnants that amplify thrombosis (13-16).

In recent months, there have been a number of descriptions of what appears to be a priori autoantibody formation in individuals with moderate-to-severe COVID-19. One example replicated by multiple groups is the detection of antiphospholipid antibodies (**aPL Abs**), which mediate antiphospholipid syndrome (**APS**) in the general population (17). In APS, patients form durable autoantibodies to phospholipids and phospholipid-binding proteins such as prothrombin and beta-2-glycoprotein I. These autoantibodies then engage cell surfaces, where they activate endothelial cells, platelets, and neutrophils (18, 19) and thereby tip the blood-endothelium interface toward thrombosis. Case reports and case series have suggested a link between COVID-19 disease severity, circulating aPL Abs, and thrombotic events (20-25). While viral infections have long been known to trigger transient aPL Abs (26-29), mechanisms by which these short-lived antibodies may be pathogenic have never been characterized. To this end, our group recently found that COVID-19 IgG fractions enriched for aPL Abs potently activate neutrophils *in vitro*, while also potentiating thrombosis when injected into mice (30).

Beyond aPL Abs, autoantibodies against the type I interferon response (31, 32) and platelets (33) have been described in moderate-to-severe COVID-19, with both demonstrating potentially important functional properties *in vitro*. At the same time, the circulating B cell compartment of COVID-19 appears reminiscent of the autoimmune disease lupus whereby naïve B cells rapidly take an extrafollicular route to becoming antibody-producing cells (34, 35), and in doing so bypass the normal tolerance checkpoints against autoimmunity provided by the germinal center.

Here, we were interested in the extent to which circulating NET remnants might be an important activator of endothelial cells. We also necessarily turned our attention to aPL Abs as markers of COVID-19 serum with strong endothelial cell activating-potential.

RESULTS

Activation of HUVEC by COVID-19 serum. Serum samples were collected from 118 patients hospitalized with moderate-to-severe COVID-19 at an academic hospital. The average age was 62, while 47% were female and 42% were Black/African American (**Supplemental Table 1**); 35% were receiving mechanical ventilation, while 74% required supplemental oxygen support of any kind. Serum from the COVID-19 patients was diluted to 2.5% in culture media and then added to early-passage human umbilical vein endothelial cells (**HUVEC**) (**Figure 1A**). The expression of surface activation markers was determined after 6 hours by a custom in-cell ELISA compatible with the Biosafety Level-3 facility in which the experiments were performed (**Figure 1A**). As compared with serum samples from 40 healthy controls, the COVID-19 samples triggered an activated endothelial cell phenotype as evidenced by markedly increased surface expression of the leukocyte adhesion molecules E-selectin (**Figure 1B**), VCAM-1 (**Figure 1C**), and ICAM-1 (**Figure 1D**). Taken together, these data indicate that COVID-19 serum contains factors capable of activating endothelial cells.

Association of NET remnants with the endothelial cell-activating potential of COVID-19 serum. As discussed above, work by our group and many others have demonstrated that circulating NET remnants associate with both COVID-19 severity and coagulation system activation (11, 36). Given that NETs are known activators of endothelial cells (37-39), we asked whether NET remnants might predict the ability of a particular COVID-19 serum sample to upregulate surface E-selectin, VCAM-1, and ICAM-1. Specifically, we measured NETs in serum via quantification of cell-free DNA, MPO-DNA complexes, and citrullinated histone H3 (**Cit-H3**) (**Table 1**). Serum MPO-DNA complexes demonstrated a modest correlation with surface expression of both VCAM-1 ($r=0.256$, $p<0.01$) and ICAM-1 ($r=0.277$, $p<0.01$). Cell-free DNA and Cit-H3 both correlated with VCAM-1 only ($r=0.237$, $p<0.05$ and $r=0.224$, $p<0.05$, respectively) (**Table 1**). Beyond these relatively specific markers of NETs, we also sought correlations with general markers of thrombo-inflammation including C-reactive protein, D-dimer, and neutrophil calprotectin. Of the three markers, only neutrophil calprotectin demonstrated modest correlations with expression of the three endothelial cell surface markers ($r=0.187-0.203$, $p<0.05$) (**Table 1**). Taken together, these data demonstrate modest correlations between NETs, thrombo-inflammation in general, and the ability of COVID-19 serum to activate endothelial cells.

Association of aPL Abs with the endothelial cell-activating potential of COVID-19 serum.

Given that we recently demonstrated that aPL Abs isolated from patients with COVID-19 had the ability to stimulate neutrophils to release NETs (30), we reasoned that COVID-19 derived aPL Abs might also activate endothelial cells. We focused on the IgG and IgM isotypes of two types of aPL Abs (anticardiolipin and anti-PS/PT) that accounted for the majority of positive tests in our recent study (30). Interestingly, we detected strong and consistent correlations between all four antibodies and the three markers of endothelial cell activation (E-selectin, VCAM-1, and ICAM-1) (**Table 1**). The only correlation that was not statistically significant was between anti-PS/PT IgM and VCAM-1 ($r=0.115$, $p>0.05$) (**Table 1**). In summary, while we noted modest correlations between serum NET remnants and upregulation of E-selectin, VCAM-1, and ICAM-1, much stronger correlations were seen between various aPL Abs and endothelial cell activation as measured by surface expression of the three adhesion molecules.

Depletion of IgG alleviates HUVEC activation. While aPL Abs robustly correlated with the endothelial cell-activating potential of COVID-19 serum, we reasoned that there might be another co-circulating factor in serum that was actually driving endothelial cell activation. We therefore sought to prove or disprove whether IgG fractions from COVID-19 patients could directly activate HUVEC. To this end, we pooled serum from five COVID-19 patients with high aCL IgG and separately five patients with high anti-PS/PT IgG activity. We then subjected the serum to either mock or IgG depletion. As compared with mock depletion, IgG depletion completely mitigated the ability of both of the pooled samples to upregulate endothelial cell E-selectin (**Figure 2A**), VCAM-1 (**Figure 2B**) and ICAM-1 (**Figure 2C**). Upregulation was not though affected by pre-treatment with a pan-Fc receptor blocker, suggesting Fc independence of the antibody-mediated activation (**Supplementary Figure 1**). We next purified a small quantity of IgG from each pool, and then spiked it into control serum that had been depleted of its own IgG. The COVID-19 IgG-supplemented control serum now demonstrated an ability to increase expression of surface ICAM-1 (**Figure 2D**). Taken together, these data indicate that the presence of aPL Abs strongly associates with COVID-19 IgG samples that are able to activate endothelial cells.

DISCUSSION

Here, we report for the first time that serum from COVID-19 patients activates cultured endothelial cells to express surface adhesion molecules with a known role in thrombosis, namely E-selectin, VCAM-1, and ICAM-1. Furthermore, we found that for at least a subset of serum samples, this activation could be completely mitigated by depleting the samples of IgG. Prothrombotic aPL Abs associated strongly with these phenotypes suggesting a new mechanism by which these autoantibodies may perpetuate thrombo-inflammation in COVID-19.

The role of aPL Abs in activating endothelial cells has been demonstrated both *in vitro* and *in vivo* (40). For example, IgG fractions from APS patients have long been known to activate HUVEC, as reflected by increased monocyte adherence and expression of adhesion molecules (41) (similar to what we demonstrated here for COVID-19). In APS, aPL Abs may further promote endothelial dysfunction by antagonizing eNOS via the apoER2 receptor (42, 43). Downstream of aPL Ab engagement of the endothelial cell surface, various intracellular messengers including MyD88, NF- κ B, and AP-1 may participate in endothelial cell activation (44, 45), although exact mechanisms remain to be fully elucidated (46). Beyond canonical aPL Abs, the concept of “anti-endothelial cell antibodies” has also garnered some attention in lupus and APS (47). These autoantibodies (antigen specificity unclear) have been reported to enhance leukocyte adhesion and promote thrombosis through interference with clearance of dying cells (48) or cooperation between Fc gamma receptor IIa and CXCR1/2 (49). Whether such antibodies may exist in association with aPL Abs in COVID-19 is an interesting question deserving of further research.

In addition to our findings (30), a number of other groups have also provided evidence for pathogenic autoantibodies in COVID-19 (31, 33, 50). For example, a recent study detected autoantibodies against type I IFNs (13.7%) in patients with life-threatening COVID-19 (31), and provided evidence that these autoantibodies have the ability to neutralize interferons *ex vivo*. Another small study suggested that IgG from COVID-19 patients had the ability to induce platelet phosphatidylserine externalization and apoptosis through interactions with Fc gamma receptor IIa, which may be associated with thromboembolic complications in COVID-19 patients (33). An interesting study used a high-throughput autoantibody discovery technique to screen a cohort of COVID-19 patients for autoantibodies against 2,770 extracellular and secreted proteins (51). The authors found a tendency for autoantibodies to be directed against immunomodulatory proteins including cytokines, chemokines, complement components, and

cell surface proteins. Taken together, these findings suggest a pathological role for autoantibodies in COVID-19 with diverse impacts on immune function, thrombosis, and likely clinical outcomes.

There are several potential clinical implications of our findings. One may consider whether patients with moderate-to-severe COVID-19 should be screened for aPL Abs to evaluate their risk of thrombosis and progression to respiratory failure. Patients with high aPL Ab titers might benefit from treatments used in traditional cases of severe APS such as therapeutic anticoagulation, complement inhibition, and plasmapheresis (52). These findings also suggest other potential therapies including monoclonal antibody-mediated depletion of plasmablasts, the specific inhibition of B cells reactive against phospholipids and phospholipid-binding proteins, endothelial cell-stabilizing therapies, and manipulation of pathogenic-antibody Fc glycosylation or afucosylation (53-55); all are potentially worthy of future research.

This study has some limitations including reliance on serum samples discarded by the clinical laboratory, a lack of a direct readout of thrombosis given aggressive anticoagulation used at our center early in the pandemic, and a so far incomplete understanding of mechanisms by which aPL Ab-associated IgG fractions activate endothelial cells. However, given the urgency of COVID-19 research, we believe these weaknesses are counterbalanced by the relatively large sample size and the heretofore unknown discovery of endothelial cell-activating antibodies in COVID-19 serum. Indeed, these data also put the diffuse organ involvement of COVID-19 into context, where a non-specific humoral response to the illness may disrupt the normally quiescent endothelium and potentiate vascular inflammation. As we await the definitive immunologic solutions that will hopefully end the pandemic, these findings give further context to the complex interplay between SARS-CoV-2 infection, the human immune system, and COVID-19 severity.

MATERIALS AND METHODS

Serum samples from patients with COVID-19. Blood was collected into serum separator tubes containing clot activator and serum separator gel by a trained hospital phlebotomist. After completion of biochemical testing ordered by the clinician, the samples were released to the research laboratory. Serum samples were immediately divided into small aliquots and stored at -80°C until the time of testing. All 118 patients had a confirmed COVID-19 diagnosis based on U.S. Food and Drug Administration (FDA)-approved RNA testing. This study complied with all relevant ethical regulations, and was approved by the University of Michigan Institutional Review Board (HUM00179409).

Cell culture. Human umbilical vein endothelial cells (HUVEC) were purchased from ATCC and cultured in EBM supplemented with EGM-2MV SingleQuots (Lonza) without hydrocortisone. 10,000 cells/well were seeded into 0.2% gelatin-coated 96-well tissue culture plates the day before experiments. The following day, HUVEC were cultured with 2.5% human serum or IgG at a concentration of 100 µg/ml at 37°C in a humidified atmosphere of 5% CO₂. All experiments were performed using HUVEC of passage 6 or fewer.

IgG depletion from serum. IgG was purified from COVID-19 and control serum with protein G Agarose beads (Pierce). Briefly, 800 µl of protein G agarose beads were washed at least 10 times by PBS. Then, 200 µl of serum was added and incubated with the beads at 4°C overnight. The supernatant was collected after spinning the tube at 2500xg for 5 minutes. The supernatant was the IgG depleted serum. The same volume of serum was incubated without beads under the same conditions as a mock control. Depletion was confirmed by Coomassie-stained gels.

Purification of human IgG fractions from serum. Serum was diluted in IgG binding buffer and passed through a Protein G Agarose column (Pierce) at least 5 times. IgG was then eluted with 0.1 M glycine and neutralized with 1 M Tris. This was followed by overnight dialysis against PBS at 4°C. IgG purity was verified with Coomassie staining, and concentrations were determined by BCA protein assay (Pierce) according to manufacturer's instructions. All IgG samples were determined to have endotoxin level below 0.1 EU/ml by the Pierce LAL Chromogenic Endotoxin Quantitation Kit (A39552) according to manufacturer's instructions. This kit offers high sensitivity with linear detection range of 0.01-1.0 EU/mL.

In-cell ELISA. In the Biosafety Level 3 facility, endothelial cell activation was assessed by an in-cell ELISA, which measured surface expression of E-selectin, ICAM-1, VCAM-1 on endothelial cells. Briefly, confluent monolayers of HUVEC in 96-well microplates were incubated with 2.5% serum or 100 µg/ml purified IgG for 6 hours and then fixed using the same volume of 8% paraformaldehyde for 30 minutes. Cells were blocked with 2x blocking solution (Abcam) at room temperature for 2 hours. After washing with PBS, cells were incubated with 5 µg/ml primary mouse anti-human antibodies against E-selectin (catalog BBA26, R&D), VCAM-1 (catalog BBA5, R&D), or ICAM-1 (ab2213, Abcam) at 4°C overnight. Next, 100 µl of diluted horseradish peroxidase conjugated rabbit anti-mouse IgG (1:2000, Jackson ImmunoResearch) in 1x blocking solution was added and incubated at room temperature for 1 hour. After washing thoroughly, 100 µl of TMB substrate was added blue color development was measured at OD 650 nm with a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). The signals were corrected by subtracting the mean signal of wells incubated in the absence of the primary antibody from all other readings.

Fc receptor blocking experiment. HUVEC were pretreated with the pan-Fc receptor blocker (1:50, 422301, Biolegend) for 15 minutes, and then incubated with 2.5% COVID serum or control serum for 6 hours.

Quantification of aPL Abs. aPL Abs were quantified in sera using Quanta Lite® ACA IgG, ACA IgM, ACA IgA, aPS/PT IgG, and aPS/PT IgM kits (Inova Diagnostics Inc.) according to the manufacturer's instructions. All assays are approved for clinical use and received 510(k) clearance from the FDA. Quanta Lite® aPL ELISAs (Inova Diagnostics) are well recognized by the international APS research community and are utilized by the largest international APS clinical research network registry, APS ACTION, in its core laboratories as the "gold standard" for aPL testing (56, 57). Here, IgG, IgM, and IgA aCL assays were reported in GPL, MPL, and APL units, respectively; and aPS/PT assays were reported in IgG and IgM units, all per the manufacturer's specifications.

Quantification of myeloperoxidase-DNA complexes. Myeloperoxidase-DNA complexes were quantified similarly to what has been previously described (58). This protocol used several reagents from the Cell Death Detection ELISA kit (Roche). First, a high-binding EIA/RIA 96-well plate (Costar) was coated overnight at 4°C with anti-human myeloperoxidase antibody (Bio-Rad 0400-0002), diluted to a concentration of 1 µg/ml in coating buffer (Cell Death kit). The plate

was washed two times with wash buffer (0.05% Tween 20 in PBS), and then blocked with 4% bovine serum albumin in PBS (supplemented with 0.05% Tween 20) for 2 hours at room temperature. The plate was again washed five times, before incubating for 90 minutes at room temperature with 10% serum or plasma in the aforementioned blocking buffer (without Tween 20). The plate was washed five times, and then incubated for 90 minutes at room temperature with 10x anti-DNA antibody (HRP-conjugated; from the Cell Death kit) diluted 1:100 in blocking buffer. After five more washes, the plate was developed with 3,3',5,5'-Tetramethylbenzidine (TMB) substrate (Invitrogen) followed by a 2N sulfuric acid stop solution. Absorbance was measured at a wavelength of 450 nm using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). Data were normalized to *in vitro*-prepared NET standards included on every plate, which were quantified based on their DNA content.

Quantification of cell-free DNA. Cell-free DNA was quantified in sera using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, P11496) according to the manufacturer's instructions.

Quantification of Cit-H3. Cit-H3 was quantified in sera using the Citrullinated Histone H3 (clone 11D3) ELISA Kit (Cayman, 501620) according to the manufacturer's instructions.

Quantification of S100A8/A9 (calprotectin). Calprotectin levels were measured with the Human S100A8/S100A9 Heterodimer DuoSet ELISA (DY8226-05, R&D Systems) according to the manufacturer's instructions.

Statistical analysis. Normally-distributed data were analyzed by two-sided t test and skewed data were analyzed by Mann-Whitney test when two groups were analyzed. Correlations were tested by Spearman's correlation coefficient. Data analysis was with GraphPad Prism software version 8. Statistical significance was defined as $p < 0.05$.

REFERENCES

1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020.
2. Tang N, Li D, Wang X, and Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844-7.
3. Cui S, Chen S, Li X, Liu S, and Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost.* 2020.
4. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res.* 2020.
5. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res.* 2020;191:9-14.
6. Tian S, Hu W, Niu L, Liu H, Xu H, and Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. *J Thorac Oncol.* 2020.
7. Liu X, Li Z, Liu S, Chen Z, Zhao Z, Huang Y-y, et al. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. 2020:2020.02.27.20027557.
8. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, and Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med.* 2020.
9. Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, et al. Microvascular Injury in the Brains of Patients with Covid-19. *N Engl J Med.* 2020.
10. Colling ME, and Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. *Vasc Med.* 2020:1358863X20932640.
11. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. *JCI Insight.* 2020;5(11).
12. Shi H, Zuo Y, Yalavarthi S, Gockman K, Zuo M, Madison JA, et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. *J Leukoc Biol.* 2020.
13. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J Exp Med.* 2020;217(6).
14. Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. *EBioMedicine.* 2020;58:102925.
15. Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. *Blood.* 2020;136(10):1169-79.
16. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated with Respiratory Failure and Coagulopathy. *Circulation.* 2020.
17. Madison JA, Duarte-Garcia A, Zuo Y, and Knight JS. Treatment of thrombotic antiphospholipid syndrome in adults and children. *Curr Opin Rheumatol.* 2020;32(3):215-27.
18. Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, Nunez-Alvarez C, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. *Arthritis Rheumatol.* 2015;67(11):2990-3003.
19. Zuo Y, Shi H, Li C, and Knight JS. Antiphospholipid syndrome: a clinical perspective. *Chin Med J (Engl).* 2020.

20. Devreese KMJ, Linskens EA, Benoit D, and Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation? *J Thromb Haemost.* 2020.
21. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med.* 2020;382(17):e38.
22. Gatto M, Perricone C, Tonello M, Bistoni O, Cattelan AM, Bursi R, et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. *Clin Exp Rheumatol.* 2020;38(4):754-9.
23. Siguret V, Voicu S, Neuwirth M, Delrue M, Gayat E, Stepanian A, et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? *Thromb Res.* 2020;195:74-6.
24. Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W, et al. Brief Report: Anti-phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID-19). *Arthritis Rheumatol.* 2020.
25. Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, et al. Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty? *medRxiv.* 2020.
26. Abdel-Wahab N, Talathi S, Lopez-Olivo MA, and Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. *Lupus.* 2018;27(4):572-83.
27. Asherson RA, and Cervera R. 'Primary', 'secondary' and other variants of the antiphospholipid syndrome. *Lupus.* 1994;3(4):293-8.
28. Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, and Suarez-Almazor ME. Systematic review of case reports of antiphospholipid syndrome following infection. *Lupus.* 2016;25(14):1520-31.
29. Sung J, and Anjum S. Coronavirus Disease 2019 (COVID-19) Infection Associated With Antiphospholipid Antibodies and Four-Extremity Deep Vein thrombosis in a Previously Healthy Female. *Cureus.* 2020;12(6):e8408.
30. Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. *Sci Transl Med.* 2020;12(570).
31. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science.* 2020;370(6515).
32. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;370(6515).
33. Althaus K, Marini I, Zlamal J, Pelzl L, Singh A, Häberle H, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. *Blood.* 2020.
34. Haddad NS, Nguyen DC, Kuruvilla ME, Morrison-Porter A, Anam F, Cashman KS, et al. Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection. *bioRxiv.* 2020.
35. Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. *Nat Immunol.* 2020;21(12):1506-16.
36. Zuo Y, Zuo M, Yalavarthi S, Gockman K, Madison JA, Shi H, et al. Neutrophil extracellular traps and thrombosis in COVID-19. *J Thromb Thrombolysis.* 2020.
37. Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. *FEBS Lett.* 2010;584(14):3193-7.
38. Pieterse E, Rother N, Garsen M, Hofstra JM, Satchell SC, Hoffmann M, et al. Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition. *Arterioscler Thromb Vasc Biol.* 2017;37(7):1371-9.

39. Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. *PLoS One*. 2012;7(2):e32366.
40. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, and Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. *Circulation*. 1999;99(15):1997-2002.
41. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. *J Clin Invest*. 1995;96(5):2211-9.
42. Ramesh S, Morrell CN, Tarango C, Thomas GD, Yuhanna IS, Girardi G, et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2. *J Clin Invest*. 2011;121(1):120-31.
43. Sacharidou A, Chambliss KL, Ulrich V, Salmon JE, Shen YM, Herz J, et al. Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. *Blood*. 2018;131(19):2097-110.
44. Allen KL, Hamik A, Jain MK, and McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. *Blood*. 2011;117(23):6383-91.
45. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. *Blood*. 2003;101(9):3495-500.
46. Zhang J, and McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. *Blood*. 2005;105(5):1964-9.
47. Hill MB, Phipps JL, Hughes P, and Greaves M. Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes. *Br J Haematol*. 1998;103(2):416-21.
48. Graham A, Ford I, Morrison R, Barker RN, Greaves M, and Erwig LP. Anti-endothelial antibodies interfere in apoptotic cell clearance and promote thrombosis in patients with antiphospholipid syndrome. *J Immunol*. 2009;182(3):1756-62.
49. Florey OJ, Johns M, Esho OO, Mason JC, and Haskard DO. Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc{gamma}RIIa and CXCR1/2. *Blood*. 2007;109(9):3881-9.
50. Woodruff MC, Ramonell RP, Lee FE, and Sanz I. Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection. *medRxiv*. 2020.
51. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Liu F, et al. Diverse Functional Autoantibodies in Patients with COVID-19. 2020:2020.12.10.20247205.
52. Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gomez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. *Arthritis Rheum*. 2006;54(8):2568-76.
53. Wang TT, and Ravetch JV. Functional diversification of IgGs through Fc glycosylation. *J Clin Invest*. 2019;129(9):3492-8.
54. Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Nouta J, Hoepel W, et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. *Science*. 2020.
55. Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. *Nat Immunol*. 2021;22(1):67-73.
56. Erkan D, Lockshin MD, and members AA. APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. *Lupus*. 2012;21(7):695-8.

57. Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, et al. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. *Thromb Res.* 2019;175:32-6.
58. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. *Nat Med.* 2009;15(6):623-5.

ACKNOWLEDGEMENTS

The work was supported by a grant from the Rheumatology Research Foundation to JSK and grants from the Michigan Medicine Frankel Cardiovascular Center and A. Alfred Taubman Medical Research Institute to YK and JSK. YZ was supported by a career development grant from the Rheumatology Research Foundation. JAM was partially supported by the VA Healthcare System. JSK was supported by grants from the NIH (R01HL115138), Burroughs Wellcome Fund, and Lupus Research Alliance. YK was supported by the Intramural Research Program of the NIH and NHLBI, Lasker Foundation, NIH (K08HL131993, R01HL150392), Falk Medical Research Trust Catalyst Award, and the JOBST-American Venous Forum Award.

AUTHORSHIP

HS, YZ, AAG, GS, SY, KG, JAM, JW, MZ, and YS conducted experiments and analyzed data. HS, YZ, JSK, and YK conceived the study and analyzed data. All authors participated in writing the manuscript and gave approval before submission.

Table 1: Correlation of endothelial cell activation with NET remnants and antiphospholipid antibodies in serum of patients hospitalized with COVID-19						
	E-selectin		VCAM-1		ICAM-1	
Spearman	r	p	r	p	r	p
NET remnants						
Cell-free DNA	0.057	ns	0.237	*	0.135	ns
MPO-DNA	0.145	ns	0.256	**	0.277	**
Cit-H3	0.066	ns	0.224	*	0.076	ns
Other biomarkers						
CRP	0.006	ns	0.172	ns	0.003	ns
D-dimer	0.175	ns	0.133	ns	0.258	*
Calprotectin	0.187	*	0.203	*	0.197	*
Antiphospholipid antibodies						
aCL IgG	0.450	****	0.421	****	0.346	***
aCL IgM	0.365	****	0.252	**	0.357	****
aPS/PT IgG	0.439	****	0.252	**	0.299	***
aPS/PT IgM	0.249	**	0.115	ns	0.276	**
ns=not significant; NET=neutrophil extracellular trap; MPO=myeloperoxidase; Cit-H3=citrullinated histone H3; CRP=C-reactive protein *p<0.05, **p<0.01, ***p<0.001, and **** p<0.0001						




Figure 1: Activation of human umbilical vein endothelial cells (HUVEC) by control or COVID-19 serum. (A) Schematic workflow for in-cell ELISA. HUVEC were cultured for 6 hours with serum from either healthy controls (collected pre-pandemic) or patients hospitalized with COVID-19. Cells were then fixed and surface expression of E-selectin (B), VCAM-1 (C), or ICAM-1 (D) was quantified. Median values are indicated by horizontal lines. Groups were analyzed by Mann-Whitney test; **** $p < 0.0001$.





Figure 2: Depletion of IgG from samples with high levels of anticardiolipin (aCL) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies alleviates HUVEC activation. A-C, Serum was pooled from 5 patients with high aCL IgG (>40 GPL) or 5 patients with high aPS/PT IgG (>40 IgG units). IgG was then depleted from each pool. Activation of HUVEC was determined after culture for 6 hours as defined by surface expression of E-selectin (**A**), VCAM-1 (**B**), or ICAM-1 (**C**). The experiment was repeated on 3 different days, and bars represent mean and standard deviation. Groups were compared by 2-sided paired t-test; *p<0.05 and **p<0.01. **D,** IgG (100ug/ml) was purified from the pooled samples referenced in A-C, and then spiked into control serum that had been depleted of IgG. Activation of HUVEC was determined after culture for 6 hours as defined by surface expression of ICAM-1. Groups were compared by 1-way ANOVA with correction for multiple comparisons by Tukey's test; **p<0.01.

SUPPLEMENATRY INFORMATION

Endothelial cell-activating antibodies in COVID-19

Shi *et al.*

Supplemental Table 1: Patient characteristics	
Demographics	
Number of subjects	118
Age (years) ^a	62 ± 17 (25-96)
Hospital day ^b	4 ± 5 (1-25)
Female	55 (47%)
White/Caucasian	47 (40%)
Black/African-American	50 (42%)
Comorbidities	
Diabetes	45 (38%)
Ischemic heart disease	36 (31%)
Renal disease	33 (28%)
Lung disease	29 (25%)
Autoimmune	3 (3%)
Cancer	15 (13%)
History of stroke	11 (9%)
Obesity	50 (42%)
Hypertension	73 (62%)
Immune deficiency	7 (6%)
History of smoking	23 (19%)
Medications	
Hydroxychloroquine	15 (13%)
Anti-IL6 receptor	13 (11%)
ACE inhibitor	5 (4%)
Antibiotic	38 (32%)
Antiviral	3 (3%)
Respiratory status	
Mechanical ventilation	41 (35%)
High-flow oxygen	8 (7%)
Nasal-cannula oxygen	38 (32%)
Room air	31 (26%)
^a Mean ± standard deviation	
^b Median = 3	



Supplementary Figure 1: Blocking Fc receptor does not affect HUVEC activation

triggered by COVID serum. HUVEC were pre-treated with a pan-Fc receptor blocker for 15 minutes before the addition of 2.5% pooled COVID serum. Activation of HUVEC was determined after culture for 6 hours as defined by surface expression of ICAM-1. The experiment was repeated on 3 different days, and bars represent mean and standard deviation. Groups were compared by one-way ANOVA with correction for multiple comparisons by Dunnett's test; ns=not significant.